国际肿瘤学杂志

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (7): 529-533.doi: 10.3760/cma.j.issn.1673422X.2014.07.015

• 综述 • 上一篇    下一篇

载脂蛋白A1在卵巢癌中的新应用

张军君,史健   

  1. 050011 石家庄，河北医科大学第四医院肿瘤内科
  • 出版日期:2014-08-04 发布日期:2014-08-04
  • 通讯作者: 史健, Email: shijian6668@126.com E-mail:shijian6668@126.com

New applications of apolipoprotein A1 in ovarian cancer

 ZHANG  Jun-Jun, SHI  Jian   

  1. Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China
  • Online:2014-08-04 Published:2014-08-04
  • Contact: Shi Jian E-mail:shijian6668@126.com

PDF

1283

摘要： 载脂蛋白A1（ApoA1）是血浆高密度脂蛋白的主要成分，对机体脂质运输和代谢起着重要作用，CA125作为卵巢癌的重要肿瘤标志物，已广泛用于卵巢癌的诊断和疗效检测，近来文献和数据提示ApoA1与CA125联合检测可显著提高卵巢癌早期诊断的敏感性和特异性，且研究表明ApoA1与卵巢癌的发生、发展及预后密切相关,有希望成为卵巢癌的一种新的治疗手段。

关键词: 卵巢肿瘤, 肿瘤标志, 生物学, 载脂蛋白A1

Abstract: Apolipoptotein A1 is the main component of highdensity lipoprotein cholesterol in the plasma, which plays an important role in the lipid transportation and metabolism. It is closely related with cardiovascular disease, liver disease, hereditary amyloidosis and so on. CA125， as an important biomarker， has been widely used for the diagnosis and monitoring treatment of ovarian cancer. Improved sensitivity and specificity of diagnosis are obtained when it is combined with other tumor markers, especially CA125. As reported recently， it also  is related with the generation, progress and prognosis of ovarian cancer. It has been promising to be a new kind of treatment.

Key words: Ovarian neoplasms, Tumor markers, biological, Apolipoprotein A1